智通财经APP获悉，科伦博泰生物-B(06990)涨超3%，截至发稿，涨2.28%，报350.6港元，成交额1.16亿港元。
瑞银发布研报称，科伦博泰生物-B与默沙东合作开发的靶向人滋养细胞表面抗原2(TROP2)抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)，预料将成为默沙东下一代肿瘤研发战略的核心资产，该行将sac-TMT在中国以外市场的高峰销售预测从299亿元人民币大幅上调至650亿元人民币，高于市场普遍预测的367亿元人民币。
瑞银指出，sac-TMT在中国市场销售进展顺利，2025年销售目标为8亿至10亿元人民币，当中肺癌患者使用比例已超越乳腺癌，认为该药物的潜力尚未充分反映。该行同时看好科伦博泰SKB410、SKB571、SKB535等其他ADC资产的长期增长空间，将其目标价从320.1港元上调至452.8港元，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.